GlassScriptPhysician profile
Cameale Smart
NPI 1275799439
$983.19
in general payments reported to CMS, 2019-2025
18 companies · $47.81 in 2025
The $47.81 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $21.02 · 2021: $17.26 · 2024: $337 · 2025: $47.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $384.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $185.54 | 2019-2024 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $129.07 | 2019-2024 | Breztri |
| Sanofi-Aventis U.S. LLC | $125.49 | 2019 | |
| Janssen Pharmaceuticals, INC | $66.92 | 2019 | |
| Glaxosmithkline, LLC. | $65.17 | 2024 | Trelegy Ellipta, Arexvy |
| Teva Pharmaceuticals USA, INC. | $57.28 | 2024 | Austedo Xr |
| Lilly USA, LLC | $52.61 | 2019 | |
| Exact Sciences Corporation | $50.16 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $43.78 | 2024 | |
| Merck Sharp & Dohme LLC | $31.37 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Novartis Pharmaceuticals Corporation | $30.98 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.69 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $23.45 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.50 | 2025 | Caplyta |
| Abbvie INC. | $19.25 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $17.26 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.12 | 2024 | Trintellix |
| Amgen INC. | $14.55 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameale Smart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.